| Literature DB >> 31832707 |
J M Oberson1, S Bénet1, K Redeuil1, E Campos-Giménez2.
Abstract
A novel method to quantitate vitamin D and its main metabolites (vitamin D3, vitamin D2, and their 25-hydroxy metabolites) in breast milk by supercritical fluid chromatography has been developed and fully validated. A small volume of sample (1 mL) is subjected to ethanolic protein precipitation and liquid-liquid extraction. Final extracts are derivatized with 4-phenyl-1,2,4-triazoline-3,5-dione and vitamin D derivatives analyzed by supercritical fluid chromatography hyphenated to tandem mass spectrometry with atmospheric pressure chemical ionization. Multiple reaction monitoring is used for quantitation. Separation conditions were optimized using a gradient of methanol-water-ammonium formate into carbon dioxide. Make-up solvent was methanol containing ammonium formate. The quantitation limit reached levels as low as 50 pmol/L, with intra- and inter-day relative standard deviations lower than 15% and 20% for all analytes. Accuracy was evaluated by spiking experiments and was well within acceptability ratios (± 15%). The method was then applied to a subset of commercially available human milk samples. The newly developed method provides opportunities to determine the nutritional status of mother-infant dyads from a non-invasive measure, or for interventional or observational studies building knowledge on the composition of human milk. Graphical abstract.Entities:
Keywords: Human milk; Supercritical fluid chromatography; Tandem mass spectrometry; Vitamin D
Year: 2019 PMID: 31832707 PMCID: PMC6992569 DOI: 10.1007/s00216-019-02248-5
Source DB: PubMed Journal: Anal Bioanal Chem ISSN: 1618-2642 Impact factor: 4.142
Fig. 1Chemical structure of vitamin D parent forms and main circulating metabolite 25-hydroxy vitamin D, together with C3 inactive epimer
APCI+ parameters for each vitamin D-related compound. Precursor ion was the predominant molecular ion. The pair precursor ion/product ion was used for quantitation
| Cone voltage (V) | Collision energy (eV) | Precursor ion ( | Product ion ( | |
|---|---|---|---|---|
| D2-PTAD | 30 | 15 | 572.4 | 298.1 |
| D3-PTAD | 30 | 15 | 560.4 | 298.1 |
| 25OHD2-PTAD | 30 | 17 | 570.4 | 298.1 |
| 25OHD3-PTAD | 30 | 15 | 558.4 | 298.1 |
| 3 | 30 | 20 | 570.4 | 298.1 |
| 3 | 30 | 15 | 558.4 | 298.1 |
| 1,25diOHD2-PTAD | 30 | 15 | 586.4 | 298.1 |
| 1,25diOHD3-PTAD | 30 | 15 | 574.4 | 298.1 |
| 24,25diOHD2-PTAD | 30 | 30 | 586.4 | 298.1 |
| 24,25diOHD3-PTAD | 30 | 30 | 574.4 | 298.1 |
Results of column screening. Injection of PTAD-derivatized individual solutions (100 ng/mL, 3 μL). Gradient elution, methanolwater (98:2) containing 10 mM ammonium formate into carbon dioxide. Retention times of each of the compounds in minutes, where two isomers of the PTAD derivative were separated the two values are shown. Column 1: Waters TorusTM 1-AA, column 2: Waters BEH C18, column 3: Waters CSHTM Fluoro Phenyl, column 4: Waters HSS C18 SB, column 5: Waters TorusTM Diol, column 6: Waters BEH 2-EP, column 7: Nacalai Tesque cosmocore 2,6 cholester, column 8: Thermo Fischer AcclaimTM C30, column 9: Chiral Technologies Chiralpak® AD-3
| Column number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Particle size (μm) | 1.8 | 1.7 | 1.7 | 1.8 | 1.7 | 1.7 | 2.6 | 3 | 3 | |
| ID (mm) | 3 | 3 | 3 | 3 | 3 | 3 | 2.1 | 2.1 | 4.6 | |
| L (mm) | 100 | 100 | 100 | 100 | 100 | 100 | 150 | 150 | 150 | |
| Precurson ion ( | Retention time (min) | |||||||||
| D2 | 572.4 | 3.60–3.71 | 3.02–3.04 | 2.54 | 3.18–3.30 | 2.82 | 3.74–3.77 | 6.44–6.68 | 2.76–2.89 | 5.30–5.80 |
| D3 | 560.4 | 3.58–3.69 | 3.01–3.04 | 2.55 | 3.18–3.31 | 2.82 | 3.73–3.77 | 6.48–6.70 | 2.77–2.91 | 5.44–6.99 |
| 25OHD2 | 570.4 | 4.04–4.22 | 3.39 | 2.87 | 3.24–3.32 | 3.26 | 3.94–3.98 | 4.07–4.16 | 2.58–2.71 | 6.45 |
| 3 | 570.4 | 4.18 | 3.36–3.39 | 2.81–2.91 | 3.25–3.32 | 3.25–3.28 | 3.96 | 4.38–4.44 | 2.61–2.76 | 6.80 |
| 25OHD3 | 558.4 | 4.06–4.26 | 3.41–3.43 | 2.94 | 3.27–3.35 | 3.32 | 3.96–4.02 | 4.07–4.16 | 2.61–2.75 | 6.48 |
| 3 | 558.4 | 4.21 | 3.41–3.43 | 2.90–2.96 | 3.28–3.34 | 3.30–3.34 | 3.98–4.01 | 4.38–4.44 | 2.64–2.78 | 6.66 |
| 1,25diOHD2 | 586.4 | 4.47 | 3.70 | 3.11 | 3.32 | 3.55–3.60 | 4.17 | 5.60 | 2.91 | 8.00 |
| 24,25diD2 | 586.4 | 4.35–4.57 | 3.57–3.59 | 3.06 | 3.30–3.37 | 3.48 | 4.07–4.12 | 4.94–5.03 | 2.60–2.75 | 8.10 |
| 1,25diOHD3 | 574.4 | 4.51 | 3.70 | 3.15 | 3.32 | 3.59–3.63 | 4.20–4.27 | 5.60 | 2.93 | 8.40 |
| 24,25diOHD3 | 574.4 | 4.41–4.66 | 3.58–3.63 | 3.08–3.11 | 3.31–3.40 | 3.53 | 4.12–4.18 | 4.94–5.02 | 2.67–2.83 | 7.97–8.90 |
Fig. 2Chromatographic separation of 25-hydroxy vitamin D-PTAD derivatives and their C3 inactive epimer on a Waters CSHTM Fluoro Phenyl column (1.7 μm, 3 × 100 mm). Gradient of methanol/water (98:2, v/v) containing 10 mM ammonium formate as organic modifier on carbon dioxyde. Column temperature 45 °C, Atmospheric Back Pressure Regulator 128 bar. Make-up solvent was 10 mM ammonium formate in methanol, flow rate 0.4 mL/min
SFC optimized elution gradient. Mobile phase A: carbon dioxide. Mobile phase B: 10 mM ammonium formate in methanol:water (98:2)
| Time (min) | Flow rate (mL/min) | Mobile phase A (%) | Mobile phase B (%) |
|---|---|---|---|
| 0.0 | 3.00 | 99.5 | 0.5 |
| 0.5 | 3.00 | 99.5 | 0.5 |
| 5.0 | 2.75 | 92.0 | 8.0 |
| 6.0 | 1.75 | 70.0 | 30.0 |
| 7.0 | 1.75 | 70.0 | 30.0 |
| 7.8 | 1.75 | 99.5 | 0.5 |
| 8.5 | 3.00 | 99.5 | 0.5 |
| 9.0 | 3.00 | 99.5 | 0.5 |
Fig. 3Effect of injection volume on peak shape of vitamin D2 and vitamin D3 on a Waters Acquity® UPC2TM CSHTM Fluoro-Phenyl, 3.0 × 100 mm, 1.7 μm column. Gradient elution with methanol containing ammonium formate as organic modifier
Optimization of sample preparation using post-extraction addition method. Extraction efficiency calculated from the relative difference between peak response in a human milk sample spiked before and after extraction. Composition of extraction solvents and number of extraction cycles given in brackets. PP protein precipitation, LLE liquid-liquid extraction, SN saponification
| Extraction efficiency (%) | ||||
|---|---|---|---|---|
| D3-d6 | D2-d6 | 25-OHD3-d6 | 25-OH D2-d6 | |
| SN (ethanol), LLE (hexane) | 67 | 73 | 10 | 5 |
| SN (ethanol), LLE (hexane-ethyl acetate 9:1) | 113 | 114 | 37 | 31 |
| SN (ethanol), LLE (hexane-ethyl acetate 7:3) | 144 | 136 | 65 | 68 |
| PP (ethanol), LLE (hexane-ethyl acetate 9:1, 9:1) | 107 | 112 | 106 | 101 |
| PP (ethanol), LLE (hexane-ethyl acetate 9:1, 9:1, 9:1) | 103 | 105 | 106 | 101 |
| PP (ethanol), LLE (hexane-ethyl acetate 9:1, 4:1, 4:1) | 67 | 71 | 85 | 96 |
| PP (ethanol), LLE (hexane-ethyl acetate 9:1, 4:1, 3:1) | 77 | 71 | 85 | 102 |
| PP (methanol), LLE (hexane-ethyl acetate 9:1, 4:1, 3:1) | 70 | 68 | 95 | 93 |
| PP (methanol), LLE (hexane-ethyl acetate 9:1, 4:1, 3:1) | 67 | 68 | 90 | 89 |
Fig. 4MRM chromatograms of a calibrating solution (2 ng/mL) and a spiked human milk (20 ng/100 mL)
Intra- and inter-day variability on a human milk sample. Analysis performed on n non-consecutive days in duplicate. n.a. not applicable, RSr relative standard deviation of repeatability (within-day variability), RSiR relative standard deviation of intermediate reproducibility (between-day variability)
| Vitamin D2 | Vitamin D3 | 25-OHD2 | 25-OHD3 | ||
|---|---|---|---|---|---|
| Native amount | Average (ng/100 mL) | 2.8 | 22.3 | < 2 | 19.4 |
| RSr | 37.3 % | 10.8 % | n.a. | 12.3 % | |
| RSiR | 32.7 % | 16.7 % | n.a. | 13.7 % | |
| Spiked (+ 20) | Average (ng/100 mL) | 25.5 | 49.8 | 20.8 | 39.6 |
| Accuracy | 112.0 % | 117.7 % | 104.2 % | 100.4 % | |
| RSr | 10.8 % | 7.1 % | 9.1 % | 6.9 % | |
| RSiR | 26.9 % | 11.3 % | 14.7 % | 10.7 % | |
| Spiked (+ 40) | Average (ng/100 mL) | 44.7 | n.a. | 43.4 | n.a. |
| Accuracy | 104.3 % | n.a. | 108.5 % | n.a. | |
| RSr | 9.6 % | n.a. | 8.5 % | n.a. | |
| RSiR | 14.9 % | n.a. | 14.4 % | n.a. |
Vitamin D metabolites in a subset of commercial human milk samples. Antirachitic activity (ARA) calculated as 1 IU/L = 25 pg/mL vitamin D = 5 pg/mL vitamin 25OHD [18]. Average of triplicate analysis ± standard deviation
| D2 | D3 | 25OHD2 | 25OHD3 | ARA | % 25OH ARA | |
|---|---|---|---|---|---|---|
| ng/100 mL | IU/L | |||||
| Sample 1 | 4.2 ± 0.6 | 25.8 ± 0.8 | < 2 | 18.7 ± 0.3 | 47.7 | 78% |
| Sample 2 | 3.8 ± 0.3 | 6.5 ± 0.8 | < 2 | 18.7 ± 1.9 | 40.0 | 93% |
| Sample 3 | 4.0 ± 0.8 | 19.5 ± 0.9 | < 2 | 12.8 ± 1.3 | 33.4 | 77% |
| Sample 4 | 3.7 ± 1.0 | 15.2 ± 1.7 | < 2 | 25.7 ± 1.1 | 57.5 | 89% |
| Sample 5 | 6.5 ± 0.4 | 301.1 ± 27.3 | < 2 | 25.9 ± 1.1 | 172.3 | 30% |
| Sample 6 | 3.5 ± 0.8 | 11.3 ± 0.9 | < 2 | 14.8 ± 0.9 | 34.1 | 87% |
| Sample 7 | 3.5 ± 0.3 | 19.1 ± 1.8 | < 2 | 23.5 ± 1.9 | 54.6 | 86% |